Abstract
The pharmacokinetics and bioavailability of total (bound plus unbound) and unbound disopyramide were compared following the simultaneous administration of an oral dose of disopyramide and an intravenous dose of14C-disopyramide in five normal volunteers and in 11 patients with congestive heart failure. The binding of disopyramide varied between 60 and 92% in patients and between 81 and 88% in normal subjects at postequilibrium drug concentrations of 10−7M. The binding of disopyramide to serum protein was concentration-dependent in all study subjects at serum concentrations achieved following drug administration. The association constant for the first binding site in serum from normal subjects and patients averaged 8.7X105 M−1 and 4.4X10 5 M−1, respectively (p < 0.05). The unbound clearance of disopyramide averaged 277ml/min and 209 ml/min in normal subjects and in patients (p < 0.05). When normalized for body weight, the unbound clearance between patients and normal subjects was not significantly different. The elimination half-life of unbound concentrations in normal subjects and in patients averaged 4.9 and 6.1 h, respectively (p < 0.05). The clearance and elimination half-life of total disopyramide was the same in both groups. Although the bioavailability of disopyramide averaged 0.85 in both groups, it was more variable in patients owing to the variability in the fraction of the dose absorbed. The unbound renal clearance and volume of distribution at steady state of disopyramide was related to cardiac index. The ratio of elimination half-lives of total and unbound disopyramide was related to the extent of serum protein binding.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
P. H. Hinderling and E. R. Garrett. Pharmacokinetics of the antiarrhythmic disopyramide in healthy humans.J. Pharmacokin. Biopharm. 4:199–230 (1976).
J. J. Lima, H. Boudoulas, and M. F. Blandford. Concentration-dependence of disopyramide binding to serum protein and its influence on kinetics and dynamics.J. Pharmacol Exp. Ther. 219:741–747 (1981).
J. L. Cunningham, D. D. Shen, I. Shudo, and D. L. Azarnoff. The effects of urine pH and plasma protein binding on the renal clearance of disopyramide.Clin. Pharmacokin. 2:373–383 (1977).
J. L. Cunningham, D. D. Shen, I. Shudo, and D. L. Azarnoff. The effects of non-linear disposition kinetics on the systemic availability of disopyramide.Br. J. Clin. Pharmacol. 5:343–346 (1978).
P. J. Meffln, E. W. Robert, R. A. Winkle, S. Harapat, F. A. Peters, and D. C. Harison. Role of concentration-dependent plasma protein binding in disopyramide disposition.J. Pharmacokin. Biopharm. 7:29–46 (1979).
K. C. Giacomini, S. E. Swezey, K. Turner-Tamiyasu, and T. F. Blaschke. The effect of saturable binding to plasma proteins on the pharmacokinetic properties of disopyramide.J. Pharmacokin. Biopharm. 10:1–14 (1982).
P. J. Podrid, A. Schoeneberger, and B. Lown. Congestive heart failure caused by oral disopyramide.N. Engt J. Med. 302:614–617 (1980).
J. J. Lima, J. J. MacKichan, N. Libertin, and J. R. Sabino, Influence of volume shifts on drug binding during equilibrium dialysis: correction and attenuation.J. Pharmacokin. Biopharm. 11:483–498 (1983).
H.E. Rosenthal. A graphic method for the determination and presentation of binding parameters in a complex system.Anal. Biochem. 20:525–532 (1967).
R. L. Priore and H. E. Rosenthal. A statistical method for the estimation of binding parameters in a complex system.Anal. Biochem. 70:231–240 (1976).
R. F. Mais, S. Keresztes-Nagy, J. F. Zaroslinski, and Y. T. Vester. Interpretation of protein-drug interaction through fraction bound and relative contribution of secondary sites.J. Pharm. Sci. 63:1423–1427 (1974).
H. Sandler and H. T. Dodge. Angiographic methods for determination of left ventricular geometry and volume. In: I. Mirsky, S. N. Ghista and H. Sandler (eds.),Cardiac Mechanics. Physiological, Clinical and Mathematical Considerations, Wiley, New York, 1974.
J. J. Lima. Liquid Chromatographic analysis of disopyramide and its mono-N-dealkylated metabolite.Clin. Chem. 25:405–508 (1979).
A. Karim.The pharmacokinetics of Norpace. Angiology (suppl.)I (part 2):85–98 (1975).
M. Gibaldi and D. Perrier.Pharmacokinetics, Marcel Dekker, New York, 1982.
C. M. Metzler, G. L. Elfring, and A. J. McWen. A package of computer programs for pharmacokinetic modeling.Biometrics 30:562 (1974).
J. W. Wagner. Statistics. InFundamentals of Clinical Pharmacokinetics. Drug Intelligence Publns., Hamilton, Ill., 1975, Vol. 1, pp. 286–287.
K. Landmark, J. E. Bredesen, E. Thaulow, S. Simonsen, and J. P. Amile. Pharmacokinetics of disopyramide with imminent to moderate cardiac failure.Eur. J. Clin. Pharmacol. 19:187–192 (1981).
G. R. Wilkinson and D. G. Shand. A physiological approach to hepatic drug clearance.Clin. Pharmacol. Ther. 18:377–390 (1975).
L. Z. Benet, A. Greither, and W. Meister. Gastrointestinal absorption of drugs in patients with cardiac failure. In L. Z. Benet (ed.),The Effect of Disease States on Drug Pharmacokinetics. A. Ph. A/Academy of Pharmaceutical Sciences, Washington, D. C., 1976, pp. 33–50.
W. S. Nimmo. Gastric emptying and drug absorption. In L. F. Prescott and W. S. Nimmo (eds.)Drug Absorption. Proceedings of the Edinburgh International Conference Adis Press (Australia), 1979, pp. 11–20.
M. Gibaldi and P. J. McNamara. Apparent volumes of distribution and drug binding to plasma proteins and tissues.Eur. J. Clin. Pharmacol. 13:373–378 (1978).
J. J. Lima and L. Salzer. Contamination of albumin by alpha 1-acid glycoprotein.Biochem. Pharmacol. 30:2633–2636 (1981).
K. Schmid. Alpha 1-acid glycoprotein. In F. W. Putnam (ed.),The Plasma Proteins. Academic Press, New York, 1975, Vol. 1, pp. 183–228.
C. Pollick, K. M. Giacomini, T. F. Blaschke, W. L. Nelson, K. Turner-Tamiyasu, V. B. Briskin, and R. L. Popp. The cardiac effects of d-and 1-disopyramide in normal subjects: noninvasive study.Circulation 66:447–453 (1982).
D. B. Haughey and J. J. Lima. Influence of concentration-dependent protein binding on serum concentrations and urinary excretion of disopyramide.Biopharm. Drug Dispos. 4:103–112 (1983).
J. J. Lima. Experimental evidence for concentration-dependent plasma protein binding effects on the apparent half-lives of restrictively cleared drugs.J. Pharm. Sci. 72:461–462 (1983).
P. J. McNamara, G. Levy, and M. Gibaldi. Effect of plasma protein and tissue binding on the time course of drug concentration in plasma.J. Pharmacokin. Biopharm. 7:195–206 (1979).
S. Oie, T. W. Guentert, and T. Tozer. Effect of saturable binding on the pharmacokinetics of drugs: a simulation.J. Pharm. Pharmacol. 32:471–4771 (1980).
K. Altland, T. H. Roeder, H. M. Jakin, H. G. Zimmer, and V. Neilhoff. Demonstration of alpha 1-acid glycoprotein (orosomucoid) by double one dimensional slab gel electrophoresis: evidence for intra- and interindividual variability of the microheterogeneity pattern in health and disease.Clin. Chem. 28:1000–1010 (1982).
Author information
Authors and Affiliations
Additional information
This work was supported by Grant GM-28424 from the National Institute of General Medical Sciences, National Institutes of Health.
Rights and permissions
About this article
Cite this article
Lima, J.J., Haughey, D.B. & Leier, C.V. Disopyramide pharmacokinetics and bioavailability following the simultaneous administration of disopyramide and14C-disopyramide. Journal of Pharmacokinetics and Biopharmaceutics 12, 289–313 (1984). https://doi.org/10.1007/BF01061722
Received:
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF01061722